Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

• Status: Recruiting
• Trial end date: 2027-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Calgary
• Collaborators: Canadian Institutes of Health Research (CIHR); Johns Hopkins University; University of Maryland
• Treatments: Psilocybin

Criteria

Inclusion Criteria:

• Meets DSM-5 AUD criteria of at least moderate severity

• Meets heavy drinking requirements (heavy drinking days, number of drinks) in past 30 days

• Desire to decrease alcohol consumption

• Limited lifetime hallucinogen use

Exclusion Criteria:

• Severe or moderate substance use disorder other than alcohol or nicotine in past 6 months

• Diagnosis of schizophrenia, bipolar disorders or first-degree relative with diagnosis

• Active suicidal ideation or serious attempt within past 3 years

• Currently pregnant, nursing, or trying to become pregnant

• Any notable abnormality on ECG, physical exam, or routine medical blood laboratory test